MA35636B1 - Immediate release formulation of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1H-imidazol-1-yl) -3- ( trifluoromethyl) phenyl] benzamide - Google Patents

Immediate release formulation of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1H-imidazol-1-yl) -3- ( trifluoromethyl) phenyl] benzamide

Info

Publication number
MA35636B1
MA35636B1 MA36991A MA36991A MA35636B1 MA 35636 B1 MA35636 B1 MA 35636B1 MA 36991 A MA36991 A MA 36991A MA 36991 A MA36991 A MA 36991A MA 35636 B1 MA35636 B1 MA 35636B1
Authority
MA
Morocco
Prior art keywords
methyl
benzamide
imidazol
pyridinyl
pyrimidinyl
Prior art date
Application number
MA36991A
Other languages
French (fr)
Inventor
Upkar Bhardwaj
Mangesh Sadashiv Bordawekar
Ann Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA35636B1 publication Critical patent/MA35636B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une forme de dosage solide de nilotinib comprenant : (i) un noyau comprenant du 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl-1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide ou un sel pharmaceutiquement acceptable de celui-ci et des excipients; et (ii) au moins un polymère, ledit polymère revêtant ledit noyau, la désintégration de ladite forme de dosage solide étant retardée.The invention relates to a solid dosage form of nilotinib comprising: (i) a ring comprising 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4) 1-methyl-1H-imidazol-1-yl) -3- (trifluoromethyl) phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, the disintegration of said solid dosage form being delayed.

MA36991A 2011-11-14 2014-05-07 Immediate release formulation of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1H-imidazol-1-yl) -3- ( trifluoromethyl) phenyl] benzamide MA35636B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14
PCT/US2012/064610 WO2013074432A1 (en) 2011-11-14 2012-11-12 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Publications (1)

Publication Number Publication Date
MA35636B1 true MA35636B1 (en) 2014-11-01

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36991A MA35636B1 (en) 2011-11-14 2014-05-07 Immediate release formulation of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1H-imidazol-1-yl) -3- ( trifluoromethyl) phenyl] benzamide

Country Status (22)

Country Link
EP (1) EP2779995A1 (en)
JP (1) JP6275645B2 (en)
KR (1) KR20140093230A (en)
CN (1) CN103930094A (en)
AR (1) AR088844A1 (en)
BR (1) BR112014011518A2 (en)
CA (1) CA2855503A1 (en)
CL (1) CL2014001247A1 (en)
CO (1) CO6960546A2 (en)
EA (1) EA201490960A1 (en)
GT (1) GT201400094A (en)
HK (1) HK1197025A1 (en)
IL (1) IL232480A0 (en)
IN (1) IN2014DN03416A (en)
MA (1) MA35636B1 (en)
MX (1) MX2014005874A (en)
PE (1) PE20141337A1 (en)
SG (2) SG11201401476TA (en)
TN (1) TN2014000177A1 (en)
TW (1) TWI574690B (en)
WO (1) WO2013074432A1 (en)
ZA (1) ZA201402756B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (en) 2017-12-20 2019-07-03 Zentiva, K.S. Dosing of crystalline nilotinib
JP7378279B2 (en) * 2019-11-18 2023-11-13 日本化薬株式会社 Pharmaceutical tablet containing nilotinib as an active ingredient and method for producing the same
JP7489849B2 (en) 2020-07-20 2024-05-24 日本化薬株式会社 Nilotinib tablets

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600316A (en) 2005-07-20 2007-04-02 SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
GT200600315A (en) 2005-07-20 2007-03-19 CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
IN2011CH01887A (en) * 2011-06-02 2012-12-14

Also Published As

Publication number Publication date
EP2779995A1 (en) 2014-09-24
SG11201401476TA (en) 2014-10-30
SG10201707768RA (en) 2017-10-30
AU2012339829A1 (en) 2014-05-29
TWI574690B (en) 2017-03-21
CN103930094A (en) 2014-07-16
GT201400094A (en) 2017-09-28
BR112014011518A2 (en) 2017-05-16
AR088844A1 (en) 2014-07-10
IN2014DN03416A (en) 2015-06-26
JP2014533283A (en) 2014-12-11
CO6960546A2 (en) 2014-05-30
MX2014005874A (en) 2014-06-23
TN2014000177A1 (en) 2015-09-30
HK1197025A1 (en) 2015-01-02
IL232480A0 (en) 2014-06-30
JP6275645B2 (en) 2018-02-07
EA201490960A1 (en) 2014-08-29
NZ623844A (en) 2016-09-30
ZA201402756B (en) 2015-04-29
KR20140093230A (en) 2014-07-25
AU2012339829B2 (en) 2016-05-12
TW201325594A (en) 2013-07-01
CA2855503A1 (en) 2013-05-23
WO2013074432A1 (en) 2013-05-23
PE20141337A1 (en) 2014-10-16
CL2014001247A1 (en) 2014-10-17

Similar Documents

Publication Publication Date Title
BR112013032122A2 (en) modified release of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1h-imidazol-1-yl) -3- (trifluoromethyl) phenyl] benzamide solubilized using organic acids
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
CL2012001133A1 (en) Oral pharmaceutical composition comprising ponatinib 3- (imidazo [1,2-b] pyridazin-3-ylethynyl) -4-methyl-n- (4 - ((4-methylpiperazin-1-yl) -methyl) -3- ( trifluoromethyl) phenyl) benzamide and at least one pharmaceutically acceptable excipient; and its use for the treatment of neoplasm, cancer or a hyperproliferative disorder.
EA201000702A1 (en) SOME DERIVATIVES 2-PYRAZINONE AND THEIR APPLICATION AS NEUTROFIL ELASTASIS INHIBITORS
UY32695A (en) PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A FAMILY INHIBITOR Bcl-2
CR10638A (en) USE OF HEXAN AZIBICICLO DERIVATIVES
MA35636B1 (en) Immediate release formulation of 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n- [5- (4-methyl-1H-imidazol-1-yl) -3- ( trifluoromethyl) phenyl] benzamide
MX2021002258A (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
RS54608B1 (en) Cgrp receptor antagonist
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
JP2016020375A5 (en)
ES2421587T3 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of systemic mastocytosis
MX2019001007A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases.
HRP20100265T1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
JP2012528824A5 (en)
CR20210043A (en) Pharmaceutical dosage form which can be administered orally and has modified release
BRPI0410704A (en) use of c-abltyrosine kinase inhibitor, pdgf-tyrosine kinase, or c-kit tyrosine kinase in the treatment of diabetes
MA35169B1 (en) Modified release of 4-methyl-3- [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n-5- (4-methyl-1H-imidazol-1-yl) -3- (trifluoromethyl) phenyl] ] benzamide solubilized with organic acids
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
MX2018009742A (en) Pharmaceutical composition containing imidazoline derivative.
TH152470A (en) Recipe formula 4- methyl-3 - ((4- (3-pyridyl-2-pyrimidinyl-amino) 1-N- (5- (4-methyl-1H-imi Dasol-1-il) -3- (trifluoromethyl) phenyl] benzamide instant release.
TH155598A (en) Isoxazolines as therapeutic agents ISOXAZOLINES AS THERAPEUTIC AGENTS
TH148311B (en) Modified release of 4- methyl-3 - [[4- (3-pyridinil) -2-pyrimidinyl] amino] -N- [5- (4-methyl-1H-imi Dasol-1-il) -3- (trifulformethyl) phenyl] soluble benzamides using organic acids